TICKERNERD
Menu
CVRXCVRXHealthcare · Medical Devices

CVRX Stock Forecast: CVRx, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$1.68
+0.60% on the day

The 7 Wall Street analysts covering CVRx, Inc. hold a median 12-month price target of $4.5 — +167.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$44.8M
Ticker Nerd rank
29 / 100
Median analyst target
$4.50
Analysts covering
7
Revenue$15.7M+15.6% y/y
Operating income−$13.0M
Net income−$14.0M
Free cash flow−$8.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+9.8%
1M
−42.7%
YTD
−76.3%
1Y
−81.6%
From 52W high
−84.5%
From 52W low
+9.8%
$2
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CVRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CVRx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
83
Accruals
75
Growth
61
Quality
50
Revisions
37
Volatility
32
Value
19
Issuance
18
Momentum
9

Size (83): Smaller than most of the companies we track.

Momentum (9): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CVRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CVRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12Jan 26Apr 26Jul 26Oct 26CVRXHigh $6.00Median $4.50Low $3.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
3 Buy3 Hold1 Sell
Low $3.50Median $4.50High $6.00

The green dot is the last close — the median target sits +167.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026Cantor FitzgeraldMaintainsOverweight$13 → $5.00
8 Aug 2026Lake StreetDowngradeHold—
7 Aug 2026Lake StreetDowngradeHold$14 → $3.50
14 Apr 2026Canaccord GenuityMaintainsBuy—
14 Apr 2026Canaccord GenuityMaintainsBuy$10
13 Feb 2026Canaccord GenuityMaintainsBuy—
6 Nov 2025Canaccord GenuityMaintainsBuy—
6 Nov 2025Cantor FitzgeraldMaintainsOverweight—
5 Aug 2025Cantor FitzgeraldReiteratesOverweight—
9 May 2025JP MorganDowngradeUnderweight—
9 May 2025Piper SandlerMaintainsOverweight—
8 Apr 2025Canaccord GenuityMaintainsBuy—
8 Apr 2025Lake StreetMaintainsBuy—
5 Feb 2025Canaccord GenuityMaintainsBuy—
5 Feb 2025Piper SandlerMaintainsOverweight—
17 Jan 2025Craig-HallumMaintainsBuy—
14 Jan 2025William BlairUpgradeOutperform—
9 Dec 2024Canaccord GenuityMaintainsBuy—
4 Nov 2024Craig-HallumMaintainsBuy—
30 Oct 2024Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CVRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CVRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, CVRx, Inc. returned −81.6% against +16.2% for the S&P 500, dividends included.

CVRX vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26CVRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CVRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

CVRx, Inc. (CVRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.8×

Cheaper than 82% of US stocks

Price / sales
0.7×

Cheaper than 75% of US stocks

Price / book
2.2×

Cheaper than 40% of US stocks

EV / EBITDA
−0.8×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
15.6%

Higher than 63% of US stocks

Earnings growth (YoY)
15.6%

Higher than 54% of US stocks

Gross margin
87.4%

Higher than 95% of US stocks

Operating margin
−82.9%

Higher than 15% of US stocks

Net margin
−84.9%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−133.4%

Higher than 11% of US stocks

Return on assets
−28.7%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CVRx, Inc. (CVRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CVRx, Inc. has a market value of $44.8M and an enterprise value of $39.3M.

  • Revenue in the twelve months to 30 June 2026: $61.2M. The latest quarter grew 15.6% year on year.

  • Net income over the same four quarters: −$52.0M, a −84.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.98.

  • Free cash flow in the twelve months to 30 June 2026: −$41.1M.

  • Shares outstanding: 26.6M.

  • Trailing P/E: −0.8×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • CVRx, Inc. employs 223 people — $274K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

CVRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CVRXCVRx, Inc.$44.8M
29
NNOXNano-X Imaging Ltd.$44.5M
18
XTNTXtant Medical Holdings, Inc.$45.0M
74
RPIDRapid Micro Biosystems, Inc.$42.9M
24
TELATELA Bio, Inc.$46.8M
34
SRTSSensus Healthcare, Inc.$48.9M
50
SNWVSANUWAVE Health, Inc.$50.1M
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CVRx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CVRX news & analysis

CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

GlobeNewsWire · 29 Sept 2026neutral

CVRx announced the schedule of scientific presentations featuring its Barostim device at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026, including late-breaking data and new clinical evidence. The announcement was made on September 29, 2026.

Why it matters — The presentation of late-breaking data and new clinical evidence at a major scientific meeting could draw attention to Barostim's clinical standing within the heart failure community.

CVRx Appoints John Landry as Chief Financial Officer

GlobeNewsWire · 21 Sept 2026positive

CVRx announced the appointment of John Landry as its new Chief Financial Officer. Landry brings roughly two decades of medtech and public company finance experience to the role.

Why it matters — A CVRX watcher would care because a seasoned CFO with extensive medtech and public company finance background could bring financial and strategic leadership to the company.

CVRx Secures Devoted Health Coverage for Barostim Therapy

Zacks Investment Research · 28 Aug 2026positive

CVRx has secured Devoted Health Medicare Advantage coverage for its Barostim therapy, expanding reimbursement access to approximately 466,000 members across 29 states.

Why it matters — Expanded insurance coverage could widen patient access to Barostim, potentially supporting broader adoption of CVRx's therapy.

CVRx Responds to Letter from Pointillist Family Office

GlobeNewsWire · 25 Aug 2026neutral

CVRx issued a statement in response to a public letter dated August 24, 2026, sent to its Board of Directors by Jorey Chernett of Pointillist Family Office. The company said its Board and leadership remain committed to acting in the best interests of all shareholders and regularly evaluate a full range of options to maximize shareholder value.

Why it matters — The shareholder letter and CVRx's public response signal an active, open engagement between the company's board and an investor, which CVRx watchers would follow for potential governance or strategic developments.

CVRx, Inc. Investors Who Suffered Losses Should Contact Block & Leviton LLP

Newsfile Corp · 24 Aug 2026negative

Block & Leviton LLP is investigating CVRx, Inc. for potential securities law violations and is contacting investors who lost money in their CVRx investment to learn how they might recover those losses. The firm announced the inquiry on August 24, 2026.

Why it matters — CVRX watchers would care because the company is the subject of a securities law investigation that could indicate legal or regulatory exposure for the company.

FAQ

Frequently asked questions about CVRX stock

What is the CVRX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering CVRx, Inc. have a median 12-month price target of $4.5, with estimates ranging from $3.5 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CVRX stock a buy right now?

Of the 7 analysts covering CVRx, Inc., 3 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks CVRx, Inc. 29 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CVRX?

As at 8 Oct 2026, CVRx, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).

Will CVRX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +167.9% from the last close, and Ticker Nerd's factor model ranks CVRx, Inc. 29 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CVRX stock forecast for 2030?

No analyst covering CVRx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.5 to $6 over the next 12 months.

How has CVRX stock performed over the past year?

CVRx, Inc. returned -81.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CVRx, Inc. do?

CVRx, Inc. is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular disease.

What is the latest news on CVRX?

The most recent item we track (GlobeNewsWire, 29 Sept 2026): "CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026". CVRx announced the schedule of scientific presentations featuring its Barostim device at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026, including late-breaking data and new clinical evidence. The announcement was made on September 29, 2026.

Company

About CVRx, Inc.

CVRx, Inc. is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular disease. Its flagship product, Barostim, is an implantable therapy system that delivers electrical pulses to carotid baroreceptors to help regulate autonomic nervous system activity and support cardiovascular function. The company’s current offerings center on Baroreflex Activation Therapy, a minimally invasive treatment approach used for patients with heart failure and other cardiovascular conditions. CVRx develops, manufactures, and commercializes its products in the United States, Germany, and selected international markets through direct sales and distribution channels. Headquartered in Minneapolis, Minnesota, CVRx plays a specialized role in the medical technology market by providing device-based therapies that address complex cardiac care needs.

CEO Mr. Kevin Hykes · 223 employees · United States · https://www.barostim.com